Guidance.....How could anyone expect Concordia which has a majority of their drugs sold in the UK which should finalize the Health Service Medical Supplies (Costs) Bill in the coming months and has already had many of their drugs changed from both "A & C" to "M" which puts pricing control into the hands of the DoH, no company in their right minds would make any type of estimate with the current outlook for 2017 from the UK Government.....CMA issues will be something that could be pushed out till next year and beyond as shown from previous cases such as Pfizer and others....
JMO